Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.UK-based Redx Pharma has identified a new drug development candidate with a potential to treat cancers including pancreatic, triple negative breast, and head and neck cancers.
Subscribe to our email newsletter
The candidate is the fourth to be advanced from the company’s development pipeline in the last year, with the program reaching development stage under two years.
Redx Pharma CEO Neil Murray said: "We believe this compound has the potential to be a best-in-class therapy that can treat areas of high unmet need.
"Patients with difficult to treat cancers such as pancreatic, triple negative breast cancer and head and neck cancers could potentially achieve dramatically improved outcomes."
Redx said the novel, potent small molecule Porcupine inhibitor targets the Wnt pathway, an embryonic signalling pathway that is suggested to maintain cancer stem cells in several cancer types.
The stem cells are related with tumorigenesis, metastasis, recurrence and resistance in cancer.
Redx said it will now progress trials to prepare the program for first-in-man clinical studies.
The company added that it looks forward to see the program progress in the next 12 months towards first-in-man clinical studies.
Earlier this year, Redx reached pre-clinical development stage with a new anti-infective compound designed to tackle methicillin-resistant staphylococcus aureus, the bacterium that causes potentially lethal infections in humans.